Company intelligence / Profile preview

Tianjin Fusogen Pharmaceuticals

Ownership: Private
Development stage: Phase 2

Overview

Tianjin Fusogen Pharmaceuticals is a Chinese biotech company focused on developing anti-HIV therapeutics. Its lead candidate, Sifuvirtide, is a synthetic peptide HIV fusion inhibitor targeting gp41. Sifuvirtide entered Phase 2 clinical trials in July 2006 and was developed with support from China’s national 863 Program. The company has at least three anti-HIV products in its pipeline. Clinical results for Sifuvirtide have not been widely published; the drug was designed to offer a lower-cost alternative to first-generation fusion inhibitors like T20/enfuvirtide.

Therapeutic areas: Infectious Diseases
Modalities: Synthetic peptideSmall molecule
Industry: Biotech

Drug pipeline

1 asset

sifuvirtide

Unknown

Partnerships

Supported by China’s national “863 Program” for high-tech R&D funding

Beyond the preview

Go deeper on Tianjin Fusogen Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tianjin Fusogen Pharmaceuticals.

Explore the full profile